Chains were run for 10,000,000 generations and sampled once every 100 generations. The first 25,000 trees (25%) were discarded as burn-in. The reliabilities for inferred nodes were assessed with posterior probabilities. Genetic distance and diversity were calculated using MEGA 5.1. Divergence time for lineages 'Ia' and 'Ib' in *R. rattus* was estimated with a relaxed molecular-clock model (Drummond et al., 2006), using the software BEAST v1.7.5 (Drummond and Rambaut, 2007) with HKY + G + I as the model of nucleotide substitution and 50,000,000 MCMC iterations. Both Yule and coalescent priors were used as tree models because it was uncertain whether or not lineage "Ib" represents an independently evolving species. We used 2.78–3.53 million years ago and 440–550 kya (thousand years ago) as priors for the divergences of *R. norvegicus-R. rattus* and *R. rattus-R. tanezumi*, respectively (Robins et al., 2008; Aplin et al., 2011).

Sequences of the *Mc1r* coding region from *R. rattus* were aligned and haplotypes were inferred using PHASE v 2.1 (Stephens et al., 2001; Stephens and Donnelly, 2003; Stephens and Scheet, 2005). The inferred haplotypes and 11 previously identified haplotypes from *R. tanezumi* (haplotypes 1–3) and *R. rattus* (haplotypes 4–11) (Kambe et al., 2011) were used to construct a median-joining (MJ) network (Bandelt et al., 1999) as implemented in Network® version 4.6.0.0. (Fluxus Technology, 2010).

RESULTS

Sequence diversity and affinity of black rats

All phylogenetic analyses of the *cytb* gene sequences showed a consistent topology. An NJ tree with bootstrap supports calculated by NJ, MP and ML methods and posterior probabilities under BI is illustrated in Fig. 2. Lineage names within the *R. rattus* Complex (RrC) follow the proposed nomenclature of Aplin et al. (2011). All Sri Lankan black rats associate with RrC Lineage I. However, two sub-lineages are indicated, with strong support values for reciprocal monophyly; these are labeled as 'RrC LIa' and 'RrC LIb' (Fig. 2). Sub-lineage RrC LIa includes two rats (R09 and R15) from Sri Lanka and examples of *R. rattus* drawn from numerous localities worldwide. Sequences from R09 and R15 are particularly close to examples from Oman and India (Fig. 2). Sub-lineage RrC LIb consists exclusively of the remaining 19 Sri Lankan black rat sequences. Nucleotide diversity [π] within sub-lineages RrC LIa and RrC LIb is 0.66% (95% CI: 0.40–0.92) and 0.24% (95% CI: 0.10–0.38%), respectively. Average genetic distance between sub-lineages RrC LIa and RrC LIb is 2.21% (95% CI: 1.41–3.01%). As found in previous analyses (Pagès et al., 2010; Aplin et al., 2011), our phylogenetic analyses indicate that the sister lineage of the combined RrC LIa + RrC LIb is RrC LII (Fig. 2). We follow Chinen et al. (2005) in associating RrCII with the taxon *R. tanezumi*

(Carleton and Musser, 2005). The divergence times between sub-lineages RrC LIa and RrC LIb were estimated to be 285 kya (95% CI: 152–415 kya) and 314 kya (95% CI: 220–404 kya) by Yule and coalescent priors, respectively.

Sequences of *Mc1r* from Sri Lankan *R. rattus* yielded 10 haplotypes (haplotypes a–j; Table 2). Genotypes of all individuals from Sri Lanka were homozygous for SNP 280G, which is consistent with their observed agouti fur color (Kambe et al., 2011). Nine of the 21 substitution sites were unique to rats from Sri Lanka, and no substitutions were shared by Sri Lankan rats and individuals of *R. tanezumi* as reported by Kambe et al. (2011). In contrast, three substitutions (C273T, A341G and C894T) were shared by Sri Lankan rats and *R. rattus* reported by Kambe et al. (2011) from Pakistan and Ogasawara Is., Japan.

A total of 13 genotypes were identified (Table 2). Ten of the 13 genotypes contained haplotype 9, which is also common in Pakistan (Kambe et al., 2011). Haplotype 8, which was found in Pakistan and Ogasawara Is., Japan (Kambe et al., 2011), was also found in rat R14. Other haplotypes (haplotypes 1–7, 10 and 11) detected by Kambe et al. (2011) were not found in this study.

The MJ network for *Mc1r* gene sequences contains three clusters, labeled "A", "B" and "C" (Fig. 3). Cluster "A" consists of haplotypes 1–3 from *R. tanezumi*. Cluster "B" consists of haplotypes 4–11 of Kambe et al. (2011) from *R. rattus* and three haplotypes inferred in this study. Cluster "C" consists of the other seven haplotypes inferred in this study. Haplotype 9 of Kambe et al. (2011) and haplotype b of this study differ by a single substitution and they occupy central positions of clusters "B" and "C", respectively. Sri Lankan rats R09 and R15, both members of *cytb* sub-lineage RrC LIa, each possess unique genotypes. The genotype of R15 consists of haplotypes 9 and e, both of cluster "B", while the genotype of R09 was homozygous for haplotype j of cluster "C" (Fig. 3 and Table 2). None of the haplotypes inferred for Sri Lankan rats were closely related to the haplotypes reported from *R. tanezumi*.

Sequence diversity and affinity of bandicoot rats

All 24 specimens of *B. bengalensis* collected in this study shared one *cytb* haplotype that falls outside clusters of sequences previously reported for each of *B. indica* and *B. savilei* (Table 1 and Fig. 2). One sequence previously reported as *B. bengalensis* by Michaux et al. (2007) falls within the *B. indica* cluster. Phylogenetic study based on representative sequences preserves the inferred paraphyly of *B. bengalensis*, with moderate or high support values (Fig. 2), and also indicates that *B. savilei* diverged first within the genus (Fig. 2). Whether or not *B. bengalensis* is genuinely paraphyletic for *cytb* with respect to *B. indica* depends on the veracity of the taxo-

Fig. 2. A neighbor joining tree based on *cytb* gene sequences from various *Rattus* and *Bandicota* species. Numbers at nodes are support values for the respective clades determined by the methods of NJ/MP/ML/BI. The shaded regions in the phylogenetic tree represent individuals collected in Sri Lanka. Major clades within the *Rattus rattus* Complex are enumerated in accordance with the suggestion of Aplin et al. (2011).

Table 2. Summary of variable sites of 13 observed Mc1r gene sequences found in 21 black rats from Sri Lanka and 11 previously identified haplotypes (Kambe et al., 2011) together with 10 newly deduced haplotypes (a–j) in this study

sample ID	haplotype	20	33	93	138	199	273	280	328	336	341	387	426	450	496	577	642	786	843	894	918	931	genotype
R12		C	G	A	C	C	C	G	G	G	A	A/G	A/C	G	G	G	G	A	C	C	C	G	(9, a)
R13		C	G	A/T	C	C	C	G	G	G	A	G	C	G	G	G	G	A	C	C/T	C	G	(9, i)
R14		C	G	A	C	C	C	G	G	G	A	G	C	G	G	G	G	A	C	C/T	C	G	(8, 9)
R19		C	G	A	C	C	C	G	G	G	A	G	C	G	G	G	G	A	C	C	C	G	(9, 9)
R16		C	G	A	C	C	C	G	G	G	A	A/G	C	G	G	G	A/G	A	C	C	C	G	(9, c)
R11/R21		C	G	A	C	C	C/T	G	G	G	A/G	A/G	C	G	G	G	G	A	C	C	C	G	(b, f)
R01/R03/R05/R17		C	G	A	C	C	C/T	G	G	G	A/G	G	C	G	G	G	G	A	C	C	C	G	(9, f)
R02/R18/R20		C	G	A	C	C	C/T	G	G	G	A/G	G	C	G	G	A/G	G	A	C	C	C	G	(e, f)
R04/R07/R08		C	G	A	C/T	C	C	G	G	G	A	A/G	C	G	G	G	G	A	C	C	C	G	(9, g)
R06		C	G	A	C/T	C/T	C	G	G	G	A	A/G	C	G	G	G	G	A	C	C	C	G	(9, h)
R10		C	G	A	C	C	C	G	G	G	A	A/G	C	G	A/G	G	G	A	C	C	C	G	(9, d)
R15		C	G	A	C	C	C	G	G	G	A	G	C	G	G	A/G	G	A	C	C	C	G	(9, e)
R09		C	A	A	C	C	C	G	G	G	A	A	C	G	G	G	G	A	C	C	C	G	(j, j)
	1	C	G	A	C	C	C	G	A	G	A	G	C	G	G	G	G	G	G	C	A	G	
	2	T	G	A	C	C	C	G	G	G	A	G	C	G	G	G	G	G	G	C	A	G	
	3	T	G	A	C	C	C	G	G	G	A	G	C	A	G	G	G	G	G	C	A	G	
	4	C	G	A	C	C	C	G	G	A	A	G	C	G	G	G	G	G	C	C	C	G	
	5	C	G	A	C	C	C	A	G	A	A	G	C	G	G	G	G	G	C	C	C	G	
	6	C	G	A	C	C	C	G	G	A	A	G	C	G	G	G	G	A	C	C	C	G	
	7	C	G	A	C	C	C	G	G	A	A	G	C	G	G	G	G	A	C	C	C	A	
	8	C	G	A	C	C	C	G	G	G	A	G	C	G	G	G	G	A	C	T	C	G	
	9	C	G	A	C	C	C	G	G	G	A	G	C	G	G	G	G	A	C	C	C	G	
	10	C	G	A	C	C	C	G	G	G	A	G	C	G	G	G	G	A	C	C	C	A	
	11	C	G	A	C	C	T	G	G	G	G	G	C	G	G	G	G	A	C	T	C	G	
	a	C	G	A	C	C	C	G	G	G	A	A	A	G	G	G	G	A	C	C	C	G	
	b	C	G	A	C	C	C	G	G	G	A	A	C	G	G	G	G	A	C	C	C	G	
	c	C	G	A	C	C	C	G	G	G	A	A	C	G	G	G	A	A	C	C	C	G	
	d	C	G	A	C	C	C	G	G	G	A	A	C	G	A	G	G	A	C	C	C	G	
	e	C	G	A	C	C	C	G	G	G	A	G	C	G	G	A	G	A	C	C	C	G	
	f	C	G	A	C	C	T	G	G	G	G	G	C	G	G	G	G	A	C	C	C	G	
	g	C	G	A	T	C	C	G	G	G	A	A	C	G	G	G	G	A	C	C	C	G	
	h	C	G	A	T	T	C	G	G	G	A	A	C	G	G	G	G	A	C	C	C	G	
	i	C	G	T	C	C	C	G	G	G	A	G	C	G	G	G	G	A	C	T	C	G	
	j	C	A	A	C	C	C	G	G	G	A	A	C	G	G	G	G	A	C	C	C	G	

nomic identification of the specimen represented by sequence AM408336. We suspect that it may be a misidentified specimen of B. indica.

DISCUSSION

Phylogenetic positions and evolutionary histories of Sri Lankan black rats Recent work on the genetic composition and affinity of black rats (Pagès et al., 2010; Aplin et al., 2011) has revealed a total of four deeply divergent mitochondrial lineages with inferred allopatric natural ranges centered on the Himalayan foothills (RrC LIII), southern India (RrC LI), upland Indochina and southern China (RrC LII), and lowland Indochina (possibly including the larger islands of the Malay Archipelago; RrC LIV). Two of these mtDNA lineages appear to correspond to karyotypically distinct populations that are sometimes treated as distinct species (Carleton and Musser, 2005): RrC LI with 2n = 38 R. rattus and RrC LII with 2n = 42 R. tanezumi. Populations of RrC LIII and RrC LIV are less well studied karyotypically but may be undifferentiated from RrC LII (Aplin et al., 2011). Of the four black rat mtDNA lineages, RrC LIV is the most deeply divergent, with >6% cytb sequence divergence from LI–III, which forms a monophyletic clade (Aplin et al., 2011). In contrast, the cytb sequence divergence between

Fig. 3. Median-joining network of *Mc1r* gene sequences. Open squares and triangles represent haplotypes reported by Kambe et al. (2011) from *R. r. rattus* (haplotypes 4–11) and *R. tanezumi* (haplotypes 1–3), respectively. Open circles represent haplotypes determined in this study (haplotypes a–j). Each branch between nodes represents a single nucleotide substitution. Solid circles represent unobserved intermediate haplotypes. Three clusters detected in the network are labeled A, B and C.

RrC LI *R. rattus* and RrC LII *R. tanezumi* is 3.8%, with an estimated divergence time of around 0.5 million years ago. Hybridization and introgression among the karyotypically distinct populations is inferred from intermediate karyotypes and patterns of genetic admixture for various localities in India, the western Pacific and Japan (Yosida, 1980; Chinen et al., 2005) and the USA (Lack et al., 2012; Conroy et al., 2013).

Black rats from Kandy District in the central highlands of Sri Lanka have been distinguished by some previous workers as an endemic subspecies, *R. r. kandianus* (Hinton, 1918; Ellerman, 1941). Yosida (1980) demonstrated that rats of this population possess a unique karyotype of 2n = 40, which he interpreted as a transitional state between the ancestral 2n = 42 of *R. tanezumi* and the 2n = 38 karyotype that occurs on the Indian mainland and has a worldwide distribution as a result of ship-borne dispersal out of Europe (Yosida, 1980). This idea was also supported by phylogenetic relationships inferred from isozyme profiles (Baverstock et al., 1983). Moreover, the uniqueness of Sri Lankan black rats was suggested by restriction enzyme analysis of mitochondrial DNA (mtDNA) (Brown and Simpson, 1981). The 2n = 38 karyotype was reported from black rat populations in the low-

lands of Sri Lanka (Yosida et al., 1974, 1979).

Two Sri Lankan black rats with known 2n = 40 karyotypes were independently sequenced for *cytb* by Robins et al. (2007) and Aplin et al. (2011). Both yielded a single *cytb* haplotype that belongs unambiguously to RrC LIV (Aplin et al., 2011). This finding led Aplin et al. (2011) to postulate a prehistoric or early historic introduction to Sri Lanka of black rats from an Indochinese or Indonesian source. Despite this earlier result, we failed to detect any RrC LIV *cytb* haplotypes among our sample of black rats from Kandy District of Sri Lanka. Instead, our rats yielded *cytb* sequences of two different lineages. One of these lineages, found in a minority of rats, represents the globally distributed RrC LI of Aplin et al. (2011). The other, more frequently encountered, lineage is hitherto unreported and appears to be unique to Sri Lanka. This new lineage is phylogenetically closest to RrC LI, yet the two show reciprocal monophyly. The new Sri Lankan lineage is herein designated RrC LIb to distinguish it from the more widespread RrC LI, which we relabel as RrC LIa. Genetic distinction between two groups of Sri Lankan rats is also observed in the nuclear sequences of *Mc1r*, for which MJ networks show three discrete clusters of haplotypes having strong albeit imperfect association, with individual *cytb* affinities for RrC Lineages Ia, Ib and II. The *Mc1r* gene has not been investigated among members of RrC LIV.

Our results suggest that *R. rattus* is a part of the native mammalian fauna of Sri Lanka. The divergence time estimate of 285–314 kya between the uniquely Sri Lankan sub-lineage RrC LIb and the Indian mainland sub-lineage RrC LIa falls within the prolonged period of globally low sea levels associated with Marine Isotope Stage 8, spanning the period 245–300 kya (Ehlers and Gibbard, 2007). Black rats thus appear to have invaded Sri Lanka from southern India sometime during the upper Middle Pleistocene, probably taking advantage of one or more of the numerous land-bridge connections between Sri Lanka and the continental mainland (Bossuyt et al., 2004). Any natural dispersal of black rats between the two areas during subsequent glacial episodes must have been insufficient to counter the genetic consequences of geographic isolation on the two gene pools.

Our results also point to a second invasion of black rats during recent times, resulting in interbreeding and genetic introgression. This is indicated by the detection of mtDNA sub-lineage RrC LIa in rats from Kandy District, by the presence of *Mc1r* haplotypes associated with this sub-lineage, and possibly by the pattern of karyotypic diversity reported previously by Yosida et al. (1974, 1979). Documentation of this second phase of invasion is not unexpected given the near-global dispersal of black rats with sub-lineage RrC LIa that has occurred out of both European and Indian ports (Tollenaere et al., 2010; Aplin et al., 2011; Bastos et al., 2011). Our hypothesis

of a dual invasion of Sri Lanka by black rats parallels a recent interpretation of elephant genetic diversity on the island (Vidya et al., 2009).

The significance of the 2n = 40 karyotype reported previously from Sri Lanka remains uncertain. Because we found the indigenous RrC sub-lineage Ib to be dominant in Kandy District, where the 2n = 40 karyotype occurs at high frequency (Yosida et al., 1974, 1979), we suspect that this karyotype is representative of the indigenous population of black rats. However, there are two grounds for caution. First, since we did not determine the karyotypes of rats for our study, we have no direct evidence to link sub-lineage RrC LIb with the 2n = 40 karyotype, and second, as noted above, the only individuals with confirmed 2n = 40 karyotypes have yielded mtDNA of RrC IV (Robins et al., 2007; Aplin et al., 2011). This contradictory evidence can be reconciled by postulating localized introgression into *R. r. kandianus* of mtDNA from a second recently invasive population of black rats, in this instance carrying mtDNA of RrC LIV (Aplin et al., 2011) – a hypothesis that can be tested by further genetic sampling of black rats in other localities within Sri Lanka and by determination of karyotypes as part of the research protocol.

The mis-match we observed between the *cytb* sub-lineages and the *Mc1r* haplotype group affinities of individual rats from Kandy District suggests that gene flow is occurring between the indigenous black rat population ('*R. r. kandianus*') and the more recent immigrants (*R. r. rattus*). This is consistent with the results of laboratory crosses performed by Yosida (1980), who showed that F1 and F2 hybrids were readily obtained between *R. r. kandianus* and *R. r. rattus*, albeit with reduced litter size at F2 (Yosida, 1980). An alternative interpretation is that the shared haplotypes are part of an ancestral gene pool, but this seems unlikely given the peripheral location of the shared haplotypes on the network and the otherwise highly structured nature of the MJ network. Taking into consideration both the preliminary genetic data and the results of previous crossbreeding experiments, we consider it very likely that gene flow is occurring between *R. r. kandianus* and *R. r. rattus*. Further studies using a wider suite of genetic markers will be needed to clarify the extent and evolutionary outcome of gene flow.

Phylogeny and diversity of the Sri Lankan *Bandicota* rats Although *B. bengalensis* is clearly an invasive species in parts of Southeast Asia, Sri Lanka is thought to be within its natural distribution (Carleton and Musser, 2005). Our sample of 24 individuals of *B. bengalensis* all shared a single *cytb* haplotype, which is consistent with *B. bengalensis* being a recently introduced species in Sri Lanka. However, since *B. bengalensis* is a colonial species and all 24 individuals were collected at the same locality, the result may also be an artifact of sampling. Further sampling across more localities will be needed to understand the history of *B. bengalensis* populations in Sri Lanka.

Zoonoses of Sri Lanka This study was initially sparked by a concern with the evolutionary history and ecology of zoonoses in Sri Lanka, where hantaviruses and leptospirosis have been reported as causative agents of disease (Vitarana et al., 1988; Gamage et al., 2011a, 2011b). Both of these pathogens, as well as many others, are likely transmitted by species of *Rattus* and *Bandicota* (Meerburg et al., 2009).

Our study has revealed that Sri Lankan black rats are of dual origin, with an indigenous population (*R. r. kandianus*) that probably entered Sri Lanka toward the end of the Middle Pleistocene and a more recent invasive population (*R. r. rattus*) that probably arrived within the historical period. Although interbreeding and genetic introgression are clearly occurring, our results suggest that a complete genetic admixture has yet to occur, at least in Kandy District where our study was conducted. For zoonotic disease studies, the insular populations thus provide good opportunities to assess several significant research topics, notably: 1) the extent of genetic divergence among the various major zoonoses harbored by indigenous vs. invasive black rats; and 2) how genetic differences between the two black rat populations affect the susceptibility to and transmission of any given disease.

B. indica is known as a host of Thailand virus (THAIV), a member of the hantaviruses, which are the causative agent of HFRS (Schmaljohn and Hjelle, 1997). In Sri Lanka, human cases of THAIV-related virus infections have been reported, but the animal host species has not been identified (Gamage et al., 2011b). Hantaviruses are known to be host-specific and to have coevolved with their host species (Plyusnin et al., 1996). The limited genetic studies carried out to date on the genus *Bandicota* indicate that all three recognized species are closely related (Fig. 2; also Pagès et al., 2010; Aplin et al., 2011). Either of the two species present in Sri Lanka, namely *B. bengalensis* and *B. indica*, and possibly both, may carry the pathogenic agent of THAIV-related virus infections. Further work is underway to explore these unanswered possibilities.

REFERENCES

Aplin, K. P., Chesser, T., and Have, J. T. (2003) Evolutionary biology of the genus *Rattus*: profile of an archetypal rodent pest. In: Rats, Mice and People: Rodent Biology and

Management (eds.: Singleton, G. R., Hinds, L. A., Krebs, J., and Spratt, D. M.), pp. 487–498. ACIAR Monograph 96, Australian Centre for International Agricultural Research, Canberra.

Aplin, K. P., Suzuki, H., Chinen, A. A., Chesser, R. T., Ten Have, J., Donnellan, S. C., Austin, J., Frost, A., Gonzalez, J. P., Herbreteau, V., et al. (2011) Multiple geographic origins of commensalism and complex dispersal history of black rats. PLoS One 6, e26357.

Bambaradeniya, C. N. B. (2006) The Fauna of Sri Lanka: Status of Taxonomy, Research and Conservation. The World Conservation Union, Colombo.

Bandelt, H. J., Forster, P., and Rohl, A. (1999) Median-joining networks for inferring intraspecific phylogenies. Mol. Biol. Evol. 16, 37–48.

Bastos, A. D., Nair, D., Taylor, P. J., Brettschneider, H., Kirsten, F., Mostert, E., von Maltitz, E., Lamb, J. M., van Hooft, P., Belmain, S. R., et al. (2011) Genetic monitoring detects an overlooked cryptic species and reveals the diversity and distribution of three invasive Rattus congeners in South Africa. BMC Genet. 12, 26.

Baverstock, P. R., Adams, M., Maxson, L. R., and Yosida, T. H. (1983) Genetic differentiation among karyotypic forms of the black rat, Rattus rattus. Genetics 105, 969–983.

Bharti, A. R., Nally, J. E., Ricaldi, J. N., Matthias, M. A., Diaz, M. M., Lovett, M. A., Levett, P. N., Gilman, R. H., Willig, M. R., Gotuzzo, E., et al. (2003) Leptospirosis: a zoonotic disease of global importance. Lancet Infect. Dis. 3, 757–771.

Bi, Z., Formenty, P. B., and Roth, C. E. (2008) Hantavirus infection: a review and global update. J. Infect. Dev. Ctries 2, 3–23.

Bossuyt, F., Meegaskumbura, M., Beenaerts, N., Gower, D. J., Pethiyagoda, R., Roelants, K., Mannaert, A., Wilkinson, M., Bahir, M. M., Manamendra-Arachchi, K., et al. (2004) Local endemism within the Western Ghats-Sri Lanka biodiversity hotspot. Science 306, 479–481.

Brown, G. G., and Simpson, M. V. (1981) Intra- and interspecific variation of the mitochondrial genome in Rattus norvegicus and Rattus rattus: restriction enzyme analysis of variant mitochondrial DNA molecules and their evolutionary relationships. Genetics 97, 125–143.

Carleton, M. D., and Musser, G. G. (2005) Order Rodentia. In: Mammal Species of the World: A Taxonomic and Geographic Reference, (eds.: Wilson, D. E., and Reeder, D. M.), pp. 745–752. The Johns Hopkins University Press, Baltimore, Maryland.

Chinen, A. A., Suzuki, H., Aplin, K. P., Tsuchiya, K., and Suzuki, S. (2005) Preliminary genetic characterization of two lineages of black rats (Rattus rattus sensu lato) in Japan, with evidence for introgression at several localities. Genes Genet. Syst. 80, 367–375.

Conroy, C. J., Rowe, K. C., Rowe, K. M. C., Kamath, P. L., Aplin, K. P., Hui, L., James, D. K., Moritz, C., and Patton, J. L. (2013) Cryptic genetic diversity in Rattus of the San Francisco Bay region, California. Biol. Invasions 15, 741–758.

Drummond, A. J., and Rambaut, A. (2007) BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol. Biol. 7, 214.

Drummond, A. J., Ho, S. Y. W., Phillips, M. J., and Rambaut, A. (2006) Relaxed phylogenetics and dating with confidence. PLoS Biol. 4, 699–710.

Ehlers, J., and Gibbard, P. L. (2007) Glaciations | Overview. In: Encyclopedia of Quaternary Science (ed.: Elias, S. A.), pp. 1023–1031. Elsevier, Amsterdam.

Ellerman, J. R. (1941) The Families and Genera of Living Rodents. Vol II - Muridae. British Museum Natural History, London.

Felsenstein, J. (1981) Evolutionary trees from DNA-sequences - a maximum-likelihood approach. J. Mol. Evol. 17, 368–376.

Felsenstein, J. (1985) Confidence limits on phylogenies - an approach using the bootstrap. Evolution 39, 783–791.

Fluxus Technology Ltd. (2010) Network®. Version 4.6.0.0 [computer program]. Fluxus Technology Ltd., Suffolk, UK. Available from http://www.fluxus-engineering.com/sharenet.htm.

Gamage, C. D., Koizumi, N., Muto, M., Nwafor-Okoli, C., Kurukurusuriya, S., Rajapakse, J. R., Kularatne, S. A., Kanda, K., Lee, R. B., Obayashi, Y., et al. (2011a) Prevalence and carrier status of leptospirosis in smallholder dairy cattle and peridomestic rodents in Kandy, Sri Lanka. Vector Borne Zoonotic Dis. 11, 1041–1047.

Gamage, C. D., Yasuda, S. P., Nishio, S., Kularatne, S. A., Weerakoon, K., Rajapakse, J., Nwafor-Okoli, C., Lee, R. B., Obayashi, Y., Yoshimatsu, K., et al. (2011b) Serological evidence of Thailand virus-related hantavirus infection among suspected leptospirosis patients in Kandy, Sri Lanka. Jpn. J. Infect. Dis. 64, 72–75.

Guindon, S., Lethiec, F., Duroux, P., and Gascuel, O. (2005) PHYML Online--a web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res. 33, W557–W559.

Hinton, M. A. C. (1918) Rats and Mice as Enemies of Mankind, vol 8. Economic Series of the British Museum, London.

Huelsenbeck, J. P., Ronquist, F., Nielsen, R., and Bollback, J. P. (2001) Evolution - Bayesian inference of phylogeny and its impact on evolutionary biology. Science 294, 2310–2314.

Kambe, Y., Tanikawa, T., Matsumoto, Y., Tomozawa, M., Aplin, K. P., and Suzuki, H. (2011) Origin of agouti-melanistic polymorphism in wild black rats (Rattus rattus) inferred from Mc1r gene sequences. Zool. Sci. 28, 560–567.

Lack, J. B., Greene, D. U., Conroy, C. J., Hamilton, M. J., Braun, J. K., Mares, M. A., and Van Den Bussche, R. A. (2012) Invasion facilitates hybridization with introgression in the Rattus rattus species complex. Mol. Ecol. 21, 3545–3561.

Li, T. C., Yoshimatsu, K., Yasuda, S. P., Arikawa, J., Koma, T., Kataoka, M., Ami, Y., Suzaki, Y., Mai, L. T. Q., Hoa, N. T., et al. (2011) Characterization of self-assembled virus-like particles of rat hepatitis E virus generated by recombinant baculoviruses. J. Gen. Virol. 92, 2830–2837.

Meerburg, B. G., Singleton, G. R., and Kijlstra, A. (2009) Rodent-borne diseases and their risks for public health. Crit. Rev. Microbiol. 35, 221–270.

Michaux, J., Chevret, P., and Renaud, S. (2007) Morphological diversity of Old World rats and mice (Rodentia, Muridae) mandible in relation with phylogeny and adaptation. J. Zool. Syst. Evol. Res. 45, 263–279.

Myers, N., Mittermeier, R. A., Mittermeier, C. G., da Fonseca, G. A., and Kent, J. (2000) Biodiversity hotspots for conservation priorities. Nature 403, 853–858.

Nylander, J. A. A. (2004) MrModeltest v2. Program distributed by the author. Evolutionary Biology Centre, Uppsala University.

Pagès, M., Chaval, Y., Herbreteau, V., Waengsothorn, S., Cosson, J. F., Hugot, J. P., Morand, S., and Michaux, J. (2010) Revisiting the taxonomy of the Rattini tribe: a phylogeny-based delimitation of species boundaries. BMC Evol. Biol. 10, 184.

Plyusnin, A., Vapalahti, O., and Vaheri, A. (1996) Hantaviruses: genome structure, expression and evolution. J. Gen. Virol.

77, 2677–2687.

Posada, D., and Buckley, T. R. (2004) Model selection and model averaging in phylogenetics: Advantages of Akaike information criterion and Bayesian approaches over likelihood ratio tests. Syst. Biol. **53**, 793–808.

Robins, J. H., Hingston, M., Matisoo-Smith, E., and Ross, H. A. (2007) Identifying *Rattus* species using mitochondrial DNA. Mol. Ecol. Notes **7**, 717–729.

Robins, J. H., McLenachan, P. A., Phillips, M. J., Craig, L., Ross, H. A., and Matisoo-Smith, E. (2008) Dating of divergences within the *Rattus* genus phylogeny using whole mitochondrial genomes. Mol. Phylogenet. Evol. **49**, 460–466.

Ronquist, F., and Huelsenbeck, J. P. (2003) MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics **19**, 1572–1574.

Saitou, N., and Nei, M. (1987) The neighbor-joining method - a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. **4**, 406–425.

Schmaljohn, C., and Hjelle, B. (1997) Hantaviruses: a global disease problem. Emerg. Infect. Dis. **3**, 95–104.

Shimada, T., Sato, J. J., Aplin, K. P., and Suzuki, H. (2009) Comparative analysis of evolutionary modes in *Mc1r* coat color gene in wild mice and mustelids. Genes Genet. Syst. **84**, 225–231.

Shinohara, A., Suzuki, H., Tsuchiya, K., Zhang, Y. P., Luo, J., Jiang, X. L., Wang, Y. X., and Campbell, K. L. (2004) Evolution and biogeography of talpid moles from continental East Asia and the Japanese islands inferred from mitochondrial and nuclear gene sequences. Zool. Sci. **21**, 1177–1185.

Stephens, M., and Donnelly, P. (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. **73**, 1162–1169.

Stephens, M., and Scheet, P. (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. **76**, 449–462.

Stephens, M., Smith, N. J., and Donnelly, P. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. **68**, 978–989.

Suzuki, H., Tsuchiya, K., and Takezaki, N. (2000) A molecular phylogenetic framework for the Ryukyu endemic rodents

Tokudaia osimensis and *Diplothrix legata*. Mol. Phylogenet. Evol. **15**, 15–24.

Swofford, D. L., and Olsen, G. J. (1990) Phylogeny reconstruction. In: Molecular Systematics (eds.: Hills, D. M., and Moritz, C.), pp. 411–501. Sinauer, Sunderland.

Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011) MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. Mol. Biol. Evol. **28**, 2731–2739.

Tollenaere, C., Brouat, C., Duplantier, J. M., Rahalison, L., Rahelinirina, S., Pascal, M., Moné, H., Mouahid, G., Leirs, H., and Cosson, J. F. (2010) Phylogeography of the introduced species *Rattus rattus* in the western Indian Ocean, with special emphasis on the colonization history of Madagascar. J. Biogeogr. **37**, 398–410.

Vidya, T. N., Sukumar, R., and Melnick, D. J. (2009) Range-wide mtDNA phylogeography yields insights into the origins of Asian elephants. Proc. Biol. Sci. **276**, 893–902.

Vitarana, T., Colombage, G., Bandaranayake, V., and Lee, H. W. (1988) Hantavirus disease in Sri Lanka. Lancet **2**, 1263.

Yasuda, S. P., Vogel, P., Tsuchiya, K., Han, S. H., Lin, L. K., and Suzuki, H. (2005) Phylogeographic patterning of mtDNA in the widely distributed harvest mouse (*Micromys minutus*) suggests dramatic cycles of range contraction and expansion during the mid- to late Pleistocene. Can. J. Zool. **83**, 1411–1420.

Yosida, T. H. (1980) Cytogenetics of the Black Rat: Karyotype Evolution and Species Differentiation. University of Tokyo Press, Tokyo.

Yosida, T. H., Kato, H., Tsuchiya, K., Sagai, T., and Moriwaki, K. (1974) Cytogenetical survey of black rats, *Rattus rattus*, in southeast and central Asia, with special regard to the evolutional relationship between three geographical types. Chromosoma (Berl.) **45**, 99–109.

Yosida, T. H., Moriwaki, K., Kato, H., Tsuchiya, K., Sabaratnam, M., Arulpragasam, K. D., and Fernando, H. E. (1979) Notes on the distribution of the Ceylonese type black rats in Sri Lanka. Proc. Jpn. Acad., B **55**, 351–356.

145

World Journal of Hepatology

TOPIC HIGHLIGHT

WJH 6th Anniversary Special Issues (1): Management of hepatocellular carcinoma

Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma

Chikako Shibata, Motoyuki Otsuka, Takahiro Kishikawa, Motoko Ohno, Takeshi Yoshikawa, Akemi Takata, Kazuhiko Koike

Chikako Shibata, Motoyuki Otsuka, Takahiro Kishikawa, Motoko Ohno, Takeshi Yoshikawa, Akemi Takata, Kazuhiko Koike, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Motoyuki Otsuka, Japan Science and Technology Agency, PRESTO, Kawaguchi, Saitama 332-0012, Japan
Author contributions: Shibata C, Otsuka M and Koike K designed and wrote the manuscript; Kishikawa T, Ohno M, Yoshikawa T and Takata A prepared the tables and references.

Correspondence to: Motoyuki Otsuka, MD, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 5-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. otsukamo-tky@umin.ac.jp
Telephone: +81-3-38155411
Fax: +81-3-38140021

Abstract

MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate gene expression posttranscriptionally, targeting thousands of messenger RNAs. Long noncoding RNAs (lncRNAs), another class of noncoding RNAs, have been determined to be also involved in transcription regulation and translation of target genes. Since deregulated expression levels or functions of miRNAs and lncRNAs in hepatocellular carcinoma (HCC) are frequently observed, clinical use of noncoding RNAs for novel diagnostic and therapeutic applications in the management of HCCs is highly and emergently expected. Here, we summarize recent findings regarding deregulated miRNAs and lncRNAs for their potential clinical use as diagnostic and prognostic biomarkers of HCC. Specifically, we emphasize the deregulated expression levels of such noncoding RNAs in patients' sera as noninvasive biomarkers, a field that requires urgent improvement in the clinical surveillance of HCC. Since nucleotide-based strategies are being applied to clinical therapeutics, we further summarize clinical and preclinical trials using oligonucleotides involving the use of miRNAs and small interfering RNAs against HCC as novel therapeutics. Finally, we discuss current open questions, which must be clarified in the near future for realistic clinical applications of these new strategies.

Key words: MicroRNA; Long noncoding RNA; Hepatocellular carcinoma; Clinical trials; Biomarker

Core tip: In this review, we summarize the latest findings on deregulated microRNAs (miRNAs) and long noncoding RNAs in hepatocellular carcinomas (HCCs) with a focus on their clinical use as novel diagnostic and prognostic

biomarkers. In addition, we summarize the current status of clinical and preclinical oligonucleotide therapies including miRNAs and small interfering RNAs as novel HCC therapeutics. This review will enable the readers to understand the current status of clinical applications and knowledge of noncoding RNAs in HCC management.

INTRODUCTION

Noncoding RNAs contain multiple classes of RNAs that are not transcribed into proteins. While most noncoding RNAs studied to date are microRNAs (miRNAs), many noncoding RNAs with various lengths have also been reported.

MiRNAs are short, single-stranded RNAs that are expressed in most organisms[1-3]. Through gene expression regulation at a posttranscriptional level, miRNAs are involved in various physiological and pathological processes[4,5]. Since the discovery of miRNA lin-4 in Caenorhabditis elegans[6,7], as of August 2014, 1881 miRNA precursors and 2588 mature miRNA sequences in humans are deposited in miRBase, a miRNA database by the Sanger Institute[8]. MiRNAs are dysregulated in nearly all types of cancer[9,10], and specific signatures of aberrantly expressed miRNAs in specific cancers may have diagnostic and therapeutic implications[11,12].

Long noncoding RNAs (lncRNAs) also play crucial roles in transcription and translation[13,14]. Similar to miRNAs, their dysregulation is also associated with human cancers[15]. One of the most well-studied lncRNAs is the *HOX* transcript antisense intergenic RNA (HOTAIR). Class I homeobox genes (*HOX* in humans) encode 39 transcriptional factors initially described as master regulators of embryonic development[16] and display a unique gene network organization. HOTAIR, a 2.2-kb-long RNA residing within the *HOXC* locus, was initially described in breast cancer tissues, where it is highly expressed[17]. In addition to HOTAIR, many other lncRNAs are dysregulated in cancer tissues. Thus, lncRNAs may also be candidates for biomarker discovery and therapeutic applications in hepatocellular carcinomas (HCCs)[18].

In contrast to miRNAs and lncRNAs, short interfering RNAs (siRNAs) are double-stranded RNAs that degrade mRNAs through perfect matches with their target sequences. Although human telomerase reverse transcriptase was recently found to function as an RNA-dependent RNA polymerase and contribute to RNA silencing[19], its activities are not dominant in mammals. Additionally, endogenously produced siRNAs may play functional roles under limited

circumstances in humans[20]. However, the exogenous application of synthesized siRNAs is an attractive method that could be used to intervene in crucial gene expression under pathological conditions, including cancers[21].

HCC is the third leading cause of cancer-related mortality worldwide[22]. Although advances have been made in early detection and interventional therapies, a continuing need exists to develop novel approaches for the management of advanced HCC[23]. While many reports have described deregulated expression levels or functions of miRNAs and lncRNAs in HCCs, we will focus on the potential clinical use of noncoding RNAs in the very near future for novel diagnostic and therapeutic applications in the management of HCCs.

NONCODING RNAS AS BIOMARKERS FOR HCC

Deregulated expression levels of noncoding RNAs in HCC tissues

Although several published reports have described deregulated expression levels of miRNAs and lncRNAs in HCC tissues[18,24,25], the data thus far vary greatly. The differences may be because of several reasons, including the use of different techniques or samples as controls, normal liver tissues *vs* nonneoplastic tissues around tumors, background livers with various fibrosis staging, inflammation activities, or etiologies, such as hepatitis B, hepatitis C, or steatohepatitis, as well as the age or sex of the tissue-derived patients; any of these factors may cause the differential expression status of miRNAs. Regardless of these limitations, the plenty data about dysregulated miRNAs in HCCs suggests that noncoding RNAs play crucial roles in hepatocarcinogenesis[24].

Deregulated expression of noncoding RNAs in HCC as prognostic/diagnostic markers

Deregulated expression levels of noncoding RNAs in HCC tissues that may be clinically useful as prognostic/diagnostic markers will be described herein. The landmark paper that initially addressed this issue focused on *miR26* expression levels in HCC tissues and was published in the New England Journal of Medicine[26]. In this study, HCC showed frequently reduced levels of *miR26*, and patients exhibited low *miR26* expression with a shorter overall survival but a better response to interferon therapy, indicating that miRNA expression status is associated with survival and response to therapy.

Expression levels of miRNAs have tissue specificities. In the liver, *miR122*, *miR192*, and *miR199a/b-3p* are highly expressed miRNAs of all mRNAs in the liver[27]. The role of *miR122* loss in hepatocarcinogenesis was confirmed in a mouse model[28,29], and its expression is decreased in HCCs, especially non-viral HCCs[27]. Decreased expression of *miR122* is also linked with poor prognosis of HCC[30]. Although *miR192* was not deregulated in HCCs in previous studies, *miR199a/b-3p*

MiRNA	Expression levels in HCC	Possible targets	Ref.
MiR21	Upregulated	PTEN, AKT, C/EBPb	[32,39,58]
MiR222	Upregulated	PP2A, p27, DDIT4	[42,43,59]
MiR223	Upregulated	Stathmin	[44]
HULC	Upregulated	IGF2BP1	[45-47]

HCC: Hepatocellular carcinoma; HULC: Highly up-regulated in liver cancer; PTEN: Phosphatase and tensin-like protein; AKT: V-akt murine thymoma viral oncogene homolog; C/EBPb: CCAAT/enhancer-binding protein beta; PP2A: Protein phosphatase 2A; IGF2BP1: Insulin-like growth factor 2 MRNA binding protein 1.

is frequently decreased in HCCs[27]. In contrast, *miR21*, whose expression is increased when rat hepatectomy[31], is upregulated as an onco-miRNA, resulting in the promotion of HCC[32]. *MiR21* expression in HCC tissues confers resistance to the antitumor effect of interferon-α and 5FU combination therapy[33].

Similar to miRNAs, expression levels of lncRNAs are also dysregulated in HCC tissues[18]. Among them, HOTAIR is overexpressed in HCC tissues and may confer chemoresistance[34]. Metastasis-associated lung adenocarcinoma transcript 1, which was initially discovered as an lncRNA associated with metastasis[35], is also upregulated in HCC tissues and may be useful as a biomarker for tumor recurrence. Recently, *HOXA* transcript at the distal tip (HOTTIP) was discovered to be located in physical contiguity with the *HOXA13* gene and upregulated in HCC tissues, and this was also associated with metastasis formation and poor patient survival[36]. These results show the functional importance of lncRNA dysregulation in HCC tissues and indicate their possible use as novel prognostic and diagnostic biomarkers.

Noncoding RNAs in the sera of patients with HCC as diagnostic markers

Although α-fetoprotein (AFP), AFP-L3, and des-gamma-carboxy prothrombin are useful noninvasive biomarkers for HCC surveillance[37], novel and sensitive biomarkers that can detect early HCC are needed. The identification of tumor-specific alterations in circulating nucleic acids of patients with cancer as noninvasive methods of cancer diagnosis is encouraging[38]. Although RNAs are generally considered unstable, they are actually quite stable and readily detected in patient serum and plasma. Microarrays, polymerase chain reaction methods, and next-generation sequencing technologies are generally utilized to detect circulating noncoding RNAs.

Although many reports have described circulating miRNA levels in patients with HCC, only a few tests have been reproducible. For example, data regarding upregulation of circulating *miR21*, *miR222*, and *miR223* in patients with HCC are inconsistent[32,33,38-44]. Highly upregulated in liver cancer, a 1.6-kb lncRNA, is also upregulated in HCC tissues[45-47] and is detected in the

plasma of patients with HCC[18,48]. Although these results are encouraging, more work is needed to make the usability of circulating noncoding RNAs as novel biomarkers more reliable (Table 1). Specificity and sensitivity, as well as methods to quantitate small amounts of RNAs in sera with high reproducibility and the universal control to adjust the obtained data from differing times and samples, need to be urgently determined[49].

NONCODING RNAS AS NOVEL THERAPEUTICS AGAINST HCC

Ongoing clinical trials

Mounting evidence suggests that noncoding RNAs are frequently dysregulated in HCCs and possibly involved in oncogenesis and may therefore provide novel molecular targets as a therapeutic intervention. However, due to the complexity associated with pleiotropic miRNA functions and lncRNAs, the number of clinical trials is presently limited[50]. The leading nucleotide-targeting therapy, Miravirsen, an LNA-based *anti-miR122* against hepatitis C virus replication, has been successful in a Phase II a study[51]. In addition, MRX34, a liposome-formulated *miR-34* mimic developed by Mirna Therapeutics, produced complete HCC regression in mouse models[52], and a Phase I study is currently recruiting patients with advanced liver cancer for HCC therapeutic intervention (NCT01829971).

While siRNAs are not endogenous noncoding RNAs, they can be described as noncoding RNAs that have been tried as novel therapeutics against HCC. ALN-VSP (Alnylam Pharmaceuticals), an RNAi therapeutic targeting vascular endothelial growth factor and kinesin spindle protein, has been shown to be well tolerated in Phase I studies (NCT008822180 and NCT01158079) for the treatment of primary and metastatic liver cancer. The results demonstrated disease control lasting more than 6 mo in the majority of patients, including a complete response in a patient with endometrial cancer who had multiple liver metastases. TMK-polo-like kinase 1 (PLK1) (Tekmira Pharmaceuticals), an RNAi targeting PLK1, is also under a Phase I / II trial (NCT01437007). Early results show that TKM-PLK is well tolerated and demonstrates clinical benefits. Although primary results from these potential therapeutics are encouraging, the benefits and unexpected side effects need to be determined, especially under long-term use.

Preclinical trials

Anti-miR21 and *anti-miR221* are under development for clinical use (Regulus Therapeutics). *MiR21* is one of the most validated microRNA targets, with numerous scientific publications suggesting that *miR21* plays an important role in the initiation and progression of cancers, including liver cancer[32,53,54]. Similarly, *miR221* has been identified to be upregulated in multiple cancers including liver cancer[54-56]. *Anti-miR21* and *anti-miR221* prolonged survival time in a preclinical mouse model

Table 2 Representative noncoding RNAs under clinical and preclinical trials for hepatocellular carcinoma therapeutics

Target	Name	Content	Vendor	Current status
MiR34	MRX34	Liposome-formulated miR-34 mimic	Mirna Therapeutics	Phase I
VEGF/KSP	ALN-VSP	RNAi targeting VEGF/KSP	Alnylam Pharmaceuticals	Phase I
PLK1	TMK-PLK1	RNAi targeting PLK1	Tekmira Pharmaceuticals	Phase I / II
MiR21	Anti-miR21	Antisense against miR21	Regulus Therapeutics	Preclinical
MiR221	Anti-miR221	Antisense against miR221	Regulus Therapeutics	Preclinical
MiR7	MiR7 mimic	MiR7 mimic	MiReven	Preclinical

VEGF: Vascular endothelial growth factor; KSP: Kidney-specific cadherin; PLK1: Polo-like kinase 1.

that genetically develops HCC. An *miR7* mimic is also under development (MiReven). Mir7 targets the phosphoinositide 3-kinase (PI3K) pathway and decreases tumor growth both *in vitro* and *in vivo*[57]. These results are summarized in Table 2.

CHALLENGES FOR BETTER CLINICAL TRANSLATION

Several other miRNAs, including lncRNAs, which are dysregulated in HCCs, can be attractive therapeutic targets by RNA mimics, antisense RNA, or siRNA. In fact, many publications have reported their efficacy. However, obstacles remain to be addressed[24]: (1) The more reproducibility of the results should be achieved to make the data more reliable; (2) Identification of driver miRNAs in oncogenesis is important to develop therapeutics targeting such miRNAs, although we may be able to use passive miRNAs as prognostic and diagnostic bio-markers; and (3) The delivery methods of oligonucleotides into specific tissues with improved oligonucleotide modification, and safety need to be seriously considered for utilizing miRNAs in clinical applications. Because miRNAs generally target multiple mRNAs, unexpected outcomes, "off-target effects," may occur, even when targeting a single miRNA.

More research to solve these issues is definitely needed for the improved translational application utilizing the data about miRNAs in HCCs.

CONCLUSION

The discovery of miRNAs and lncRNAs has opened up new possibilities for novel diagnostic and therapeutic tools against HCCs. However, several important issues remain to be resolved. We must conduct continuous research to develop innovative and useful applications of the miRNA data in the clinical management of HCCs.

REFERENCES

1   Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. *Cell* 2012; **149**: 515-524 [PMID: 22541426 DOI: 10.1016/j.cell.2012.04.005]
2   Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. *Cell* 2014; **157**: 77-94 [PMID: 24679528 DOI: 10.1016/j.cell.2014.03.008]
3   Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. *Cell* 2012; **148**: 1172-1187 [PMID: 22424228 DOI: 10.1016/j.cell.2012.02.005]
4   Ambros V. The functions of animal microRNAs. *Nature* 2004; **431**: 350-355 [PMID: 15372042 DOI: 10.1038/nature02871]
5   Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; **116**: 281-297 [PMID: 14744438 DOI: 10.1016/S0092-8674(04)00045-5]
6   Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell* 1993; **75**: 843-854 [PMID: 8252621 DOI: 10.1016/0092-8674(93)90529-Y]
7   Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. *Cell* 1993; **75**: 855-862 [PMID: 8252622 DOI: 10.1016/0092-8674(93)90530-4]
8   Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. *Nucleic Acids Res* 2011; **39**: D152-D157 [PMID: 21037258 DOI: 10.1093/nar/gkq1027]
9   Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. *Nature* 2005; **435**: 834-838 [PMID: 15944708 DOI: 10.1038/nature03702]
10   Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 2006; **103**: 2257-2261 [PMID: 16461460 DOI: 10.1073/pnas.0510565103]
11   Esteller M. Non-coding RNAs in human disease. *Nat Rev Genet* 2011; **12**: 861-874 [PMID: 22094949 DOI: 10.1038/nrg3074]
12   Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat Rev Drug Discov* 2013; **12**: 847-865 [PMID: 24172333 DOI: 10.1038/nrd4140]
13   Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. *Genes Dev* 2009; **23**: 1494-1504 [PMID: 19571179 DOI: 10.1101/gad.1800909]
14   Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. *Genetics* 2013; **193**: 651-669 [PMID: 23463798 DOI: 10.1534/genetics.112.146704]
15   Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. *RNA Biol* 2012; **9**: 703-719 [PMID: 22664915 DOI: 10.4161/rna.20481]
16   Graham A, Papalopulu N, Krumlauf R. The murine and Drosophila homeobox gene complexes have common features of organization and expression. *Cell* 1989; **57**: 367-378 [PMID: 2566383]
17   Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* 2010;

464: 1071-1076 [PMID: 20393566 DOI: 10.1038/nature08975]

18   He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. *Cancer Lett* 2014; 344: 20-27 [PMID: 24183851 DOI: 10.1016/j.canlet.2013.10.021]

19   Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, Kasim V, Hayashizaki Y, Hahn WC, Masutomi K. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. *Nature* 2009; 461: 230-235 [PMID: 19701182 DOI: 10.1038/nature08283]

20   Watanabe T, Totoki Y, Toyoda A, Kaneda M, Kuramochi-Miyagawa S, Obata Y, Chiba H, Kohara Y, Kono T, Nakano T, Surani MA, Sakaki Y, Sasaki H. Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. *Nature* 2008; 453: 539-543 [PMID: 18404146 DOI: 10.1038/nature06908]

21   Sehgal A, Vaishnaw A, Fitzgerald K. Liver as a target for oligonucleotide therapeutics. *J Hepatol* 2013; 59: 1354-1359 [PMID: 23770039 DOI: 10.1016/j.jhep.2013.05.045]

22   Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55: 74-108 [PMID: 15761078]

23   Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. *Br J Cancer* 2009; 100: 19-23 [PMID: 19018262]

24   Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Shibata C, Koike K. The role of microRNAs in hepato-carcinogenesis: current knowledge and future prospects. *J Gastroenterol* 2014; 49: 173-184 [PMID: 24258409 DOI: 10.1007/s00535-013-0909-8]

25   Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C, Migliore C, Kowalik MA, Ledda-Columbano GM, Giordano S, Columbano A. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). *Hepatology* 2014; 59: 228-241 [PMID: 23857252 DOI: 10.1002/hep.26616]

26   Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. *N Engl J Med* 2009; 361: 1437-1447 [PMID: 19812400 DOI: 10.1056/NEJMoa0901282]

27   Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. *Cancer Cell* 2011; 19: 232-243 [PMID: 21316602 DOI: 10.1016/j.ccr.2011.01.001]

28   Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. *J Clin Invest* 2012; 122: 2871-2883 [PMID: 22820288]

29   Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. *J Clin Invest* 2012; 122: 2884-2897 [PMID: 22820290]

30   Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. *Nat Commun* 2011; 2: 338 [PMID: 21654638 DOI: 10.1038/ncomms1345]

31   Castro RE, Ferreira DM, Zhang X, Borralho PM, Sarver AL, Zeng Y, Steer CJ, Kren BT, Rodrigues CM. Identification

of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. *Am J Physiol Gastrointest Liver Physiol* 2010; 299: G887-G897 [PMID: 20689055 DOI: 10.1152/ajpgi.00216.2010]

32   Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology* 2007; 133: 647-658 [PMID: 17681183 DOI: 10.1053/j.gastro.2007.05.022]

33   Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. *Br J Cancer* 2010; 103: 1617-1626 [PMID: 20978511 DOI: 10.1038/sj.bjc.6605958]

34   Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, Shang JL, Gao CF, Zhang FR, Wang F, Sun SH. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. *Hepatology* 2011; 54: 1679-1689 [PMID: 21769904 DOI: 10.1002/hep.24563]

35   Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. *Oncogene* 2003; 22: 8031-8041 [PMID: 12970751 DOI: 10.1038/sj.onc.1206928]

36   Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, Andersen JB, Hämmerle M, Tornillo L, Heim MH, Diederichs S, Cillo C, Terracciano LM. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. *Hepatology* 2014; 59: 911-923 [PMID: 24114970 DOI: 10.1002/hep.26740]

37   Huang J, Zeng Y. Current clinical uses of the biomarkers for hepatocellular carcinoma. *Drug Discov Ther* 2014; 8: 98-99 [PMID: 24815586 DOI: 10.5582/ddt.8.98]

38   Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. *J Clin Gastroenterol* 2011; 45: 355-360 [PMID: 21278583 DOI: 10.1097/MCG.0b013e3181f18ac2]

39   Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. *Mol Carcinog* 2011; 50: 136-142 [PMID: 21229610 DOI: 10.1002/mc.20712]

40   Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. *Biochem Biophys Res Commun* 2011; 406: 70-73 [PMID: 21295551 DOI: 10.1016/j.bbrc.2011.01.111]

41   Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T, Doki Y, Mori M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. *J Hepatol* 2012; 56: 167-175 [PMID: 21749846 DOI: 10.1016/j.jhep.2011.04.026]

42   Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. *PLoS One* 2011; 6: e28486 [PMID: 22174818 DOI: 10.1371/journal.pone.0028486]

43   Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. *Clin Cancer Res* 2010; 16: 867-875 [PMID: 20103675 DOI: 10.1158/1078-0432.CCR-09-1840]

44   Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of

Stathmin1. *Gastroenterology* 2008; **135**: 257-269 [PMID: 18555017 DOI: 10.1053/j.gastro.2008.04.003]

45   **Hämmerle M**, Gutschner T, Uckelmann H, Ozgur S, Fiskin E, Gross M, Skawran B, Geffers R, Longerich T, Breuhahn K, Schirmacher P, Stoecklin G, Diederichs S. Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). *Hepatology* 2013; **58**: 1703-1712 [PMID: 23728852 DOI: 10.1002/hep.26537]

46   **Panzitt K**, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. *Gastroenterology* 2007; **132**: 330-342 [PMID: 17241883 DOI: 10.1053/j.gastro.2006.08.026]

47   **Liu Y**, Pan S, Liu L, Zhai X, Liu J, Wen J, Zhang Y, Chen J, Shen H, Hu Z. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. *PLoS One* 2012; **7**: e35145 [PMID: 22493738 DOI: 10.1371/journal.pone.0035145]

48   **Xie H**, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. *Biomed Res Int* 2013; **2013**: 136106 [PMID: 23762823 DOI: 10.1155/2013/136106]

49   **Zhang LY**, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). *J Biol Chem* 2013; **288**: 4035-4047 [PMID: 23212913 DOI: 10.1074/jbc.M112.410506]

50   **Shibata C**, Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Koike K. Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. *Molecular and Cellular Therapies* 2013; **1**: 5 [DOI: 10.1186/2052-8426-1-5]

51   **Janssen HL**, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. *N Engl J Med* 2013; **368**: 1685-1694 [PMID: 23534542 DOI: 10.1056/NEJMoa1209026]

52   **Xu Y**, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi

H, Shen H, Hu Z. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. *Int J Cancer* 2011; **128**: 412-417 [PMID: 20309940 DOI: 10.1002/ijc.25342]

53   **Bao L**, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, Wu M, Su C, Chen J. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. *Cancer Lett* 2013; **337**: 226-236 [PMID: 23684551 DOI: 10.1016/j.canlet.2013.05.007]

54   **Gao P**, Wong CC, Tung EK, Lee JM, Wong CM, Ng IO. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. *J Hepatol* 2011; **54**: 1177-1184 [PMID: 21145831 DOI: 10.1016/j.jhep.2010.09.023]

55   **Gramantieri L**, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. *Clin Cancer Res* 2009; **15**: 5073-5081 [PMID: 19671867 DOI: 10.1158/1078-0432.CCR-09-0092]

56   **Callegari E**, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D'Abundo L, Ferracin M, Bassi C, Zagatti B, Corrà F, Miotto E, Lupini L, Bolondi L, Gramantieri L, Croce CM, Sabbioni S, Negrini M. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. *Hepatology* 2012; **56**: 1025-1033 [PMID: 22473819 DOI: 10.1002/hep.25747]

57   **Fang Y**, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. *Hepatology* 2012; **55**: 1852-1862 [PMID: 22234835 DOI: 10.1002/hep.25576]

58   **Wang Z**, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* 2009; **10**: 57-63 [PMID: 19015660 DOI: 10.1038/nrg2484]

59   **Pineau P**, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. *Proc Natl Acad Sci USA* 2010; **107**: 264-269 [PMID: 20018759 DOI: 10.1073/pnas.0907904107]

The Japanese Society
of Gastroenterology

The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects

Motoyuki Otsuka · Takahiro Kishikawa ·
Takeshi Yoshikawa · Motoko Ohno ·
Akemi Takata · Chikako Shibata · Kazuhiko Koike

Abstract MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate gene expression post-transcriptionally through complementary base pairing with thousands of messenger RNAs. Although the precise biological functions of individual miRNAs are still unknown, miRNAs are speculated to play important roles in diverse biological processes through fine regulation of their target gene expression. A growing body of data indicates the deregulation of miRNAs during hepatocarcinogenesis. In this review, we summarize recent findings regarding deregulated miRNA expression and their possible target genes in hepatocarcinogenesis, with emphasis on inflammation-related hepatocarcinogenesis. Because miRNA-based strategies are being applied to clinical therapeutics, precise knowledge of miRNA functions is crucial both scientifically and clinically. We discuss the current open questions from these points of view, which must be clarified in the near future.

Keywords MicroRNA · Hepatocarcinogenesis · Inflammation

Introduction

MicroRNAs (miRNAs) are short, single-stranded, noncoding RNAs, which are expressed in most organisms, from plants to vertebrates [1]. Since the discovery of the miRNA lin-4 in *Caenorhabditis elegans* [2, 3], 1,872 miRNA precursors and 2,578 mature miRNA sequences in humans have been deposited in miRBase, a public repository hosted by the Sanger Institute, as of November 2013 [4]. Bioinformatic predictions suggest that miRNAs regulate more than 30 % of human protein-coding genes [5–7]. Through the regulation of gene expression, miRNAs are involved in various physiological and pathological processes, including cell proliferation, apoptosis, differentiation, metabolism, oncogenesis and oncogenic suppression [8, 9]. Thus, it is not surprising that deregulation of miRNAs is linked closely to various human pathological conditions. In this review, we will describe the crucial role of miRNAs in liver carcinogenesis, especially inflammation-related hepatocarcinogenesis.

Biogenesis and functions of miRNAs

Transcription is the first step in miRNA expression (Fig. 1). Similar to most protein-coding genes, transcriptional factors, enhancers and silencers are involved in miRNA transcription [10–12]. Epigenetic mechanisms, such as promoter methylation or histone modification, also regulate miRNA transcription, and it was shown that histone deacetylase (HDAC) inhibition results in transcriptional changes in ~40 % of miRNAs [13].

Primary miRNAs, which possess stem-loop structures, are transcribed by RNA polymerase II [8]. These primiRNAs are processed by a microprocessor complex

M. Otsuka (✉) · T. Kishikawa · T. Yoshikawa · M. Ohno ·
A. Takata · C. Shibata · K. Koike
Department of Gastroenterology, Graduate School of Medicine,
The University of Tokyo, 5-3-1 Hongo, Bunkyo-ku,
Tokyo 113-8655, Japan
e-mail: otsukamo-tky@umin.ac.jp

M. Otsuka
Japan Science and Technology Agency,
PRESTO, Kawaguchi, Saitama 332-0012, Japan

🖉 Springer

Fig. 1 Biogenesis of miRNAs. The primary miRNA transcript (pri-miRNA) is transcribed from the genome by RNA polymerase II or III. The microprocessor complex Drosha–DGCR8 cleaves the pri-miRNA into the precursor hairpin, pre-miRNA in the nucleus. The pre-miRNA is exported from the nucleus by exportin-5–Ran-GTP. In the cytoplasm, the RNase Dicer in complex with the double-stranded RNA-binding protein, TRBP, cleaves the pre-miRNA hairpin to its mature length. The functional strand of the mature miRNA is loaded together with Argonaute (Ago2) proteins into the RNA-induced silencing complex (RISC), where it guides RISC to silence target mRNAs through mRNA cleavage or translational repression. The passenger strand (*black*) is degraded

comprising Drosha (RNAase III) [14] and DGCR8/Pasha [15] in the nucleus [16]. The processed products are approximately 65-nucleotide hairpin-shaped precursors (pre-miRNAs) that are transported to the cytoplasm via exportin-5 [17, 18]. Pre-miRNAs are further cleaved into mature miRNAs by Drosha and Dicer RNA polymerase III. Mature miRNA duplexes are loaded onto an RNA-induced silencing complex (RISC) and are unwound into the single-stranded mature form [19–21]. The resulting co-complex directly targets the 3′-untranslated regions (3′-UTRs) of target mRNAs, depending on the sequence similarities, to negatively regulate their expression by enhancing mRNA cleavage or inhibiting translation (Fig. 1) [8, 22]. Because most miRNAs guide the recognition of imperfect matches of target mRNAs, individual miRNAs have multiple (probably hundreds) of mRNA targets. In addition, multiple miRNAs can cooperate to regulate the expression of the same transcript [6]. Thus, depending upon the identity of the target mRNAs, miRNAs play roles as "fine-tuners of gene expression" in the control of various biological functions.

Identifying functionally important miRNA target genes is crucial for understanding the impact of specific miRNAs on cellular function. However, this is challenging because

miRNAs usually have imperfect complementarity with their targets [22]. In mammals, the most consistent requirement for miRNA-target interaction, although not always essential, is a contiguous and perfect pairing of the miRNA (nt 2–8), representing the "seed" sequence [22]. In many cases, the seed sequences determine this recognition, but in other cases, additional determinants are required, such as reasonable complementarity to the miRNA 3′ half to stabilize the interaction. In addition, target pairing to the center of some miRNAs has also been reported [23]. Although public miRNA target prediction algorithms, such as TargetScan [24] and PicTar [25], have facilitated the rapid identification of miRNA target genes [22], candidates should be validated experimentally.

miRNAs and cancer

The involvement of miRNAs in cancer pathogenesis is well established. miRNAs can affect six hallmarks of malignant cells, which are (1) self-sufficiency in growth signals, (2) insensitivity to anti-growth signals, (3) evasion of apoptosis, (4) limitless replicative potential, (5) angiogenesis, and (6) invasion and metastasis [26]. miRNAs are frequently

up- or downregulated in malignant tissues and can be considered oncogenes or tumor suppressors, respectively. However, it is essential to test experimentally whether the deregulated miRNAs are actually causative to carcinogenesis, since miRNAs have a very restricted tissue-specific expression and the apparent miRNA modulation in cancer tissues may only reflect the different constituents of a cell population as compared to normal tissues. Extensive analyses have confirmed the causative roles of miRNAs in cancer by using either human cancer cells or genetically engineered animal models, such as transgenic expression of miR-155, miR-21 and miR-15-a/16-1, which are sufficient to initiate lymphomagenesis in mice [27–29]. These results suggest the potential role of miRNAs in the pathogenesis of carcinogenesis and as therapeutic targets.

miRNAs and hepatocarcinogenesis

Numerous reports regarding the deregulated expression of miRNAs in human hepatocellular carcinoma (HCC) are extant. Most studies compared the miRNA expression levels between cancer tissues and background non-tumorous tissues, selected candidate miRNA(s) and revealed their target genes, which may be involved in carcinogenesis. As shown in Tables 1 and 2, many miRNAs have been identified as downregulated or upregulated in recent studies (Tables 1, 2). However, these numerous results are not always superimposable due to the large variances in the results. These significant differences may be due to several reasons, such as the use of different techniques or different samples as controls, normal liver tissues versus peritumoral non-neoplastic tissues. In addition, one may need to take into consideration the fact that HCCs arise in background livers with different etiologies, such as hepatitis B, hepatitis C or steatohepatitis, and also the age or sex of the tissue-derived patients and background liver condition, such as fibrosis staging or inflammation activity, which may result in differences in the expression status of miRNAs. Despite these considerable limitations, the list suggests that diverse miRNAs play crucial roles in hepatocarcinogenesis. We will briefly describe some of them below.

The expression levels of miRNAs have restricted tissue specificities. In the liver, miR-122, miR-192 and miR-199a/b-3p are the three most expressed miRNAs, accounting for 52, 17 and 5 % of all mRNAs in the tissues, respectively [30]. The tumorigenic role of the loss of miR-122 was confirmed in gene-knockout mice [31, 32] and its expression is indeed decreased in half of the HCCs, especially non-viral HCCs [30]. We also reported that decreased expression of miR-122 is linked with poor prognosis of HCC [33]. While miR-192 does not appear to

be deregulated in HCC samples in previous studies, miR-199a/b-3p is decreased with high frequency in HCC, which is closely linked to a poor prognosis of HCC [30]. In contrast, miR-21, whose expression is increased following rat hepatectomy [34], is upregulated as a known oncomiRNA and represses PTEN signaling, resulting in promotion of HCC development [35]. Although individual miRNAs may be involved in hepatocarcinogenesis, because miRNAs often function co-operatively, the extent of their involvement remains to be determined.

As described above, miRNAs usually have multiple mRNA targets. Thus, it is not practical to describe only a few genes as being responsible for the phenotypes by deregulation of specific miRNAs, while many studies identify specific genes as targets of specific miRNAs. Nonetheless, the identified targeted genes are generally related to at least one of the hallmarks of cancer, such as cell growth, apoptosis, invasion, and so on. These results suggest that the deregulation of miRNA expression might mediate hepatocarcinogenesis through deregulating the expression of their target genes.

The miRNAs identified as deregulated in hepatocarcinogenesis may be useful as diagnostic and prognostic markers [36], because miRNAs in the circulation are reported to be relatively stable [37]. Also, deregulated miRNAs may be candidate therapeutic and preventive targets against HCC. However, to include the obtained results in clinical interventional applications, it is necessary to confirm if the deregulated miRNAs are truly drivers or are simply passive in hepatocarcinogenesis. To this end, genetically modified mice may provide some information. In addition, to correctly interpret the data, a standard method of normalizing the microRNAome data between studies may also be crucial. Since there are multiple target genes of miRNAs and, conversely, one transcript can be targeted by multiple miRNAs, a more systematic comparison using miRNA data, transcriptome data and proteome data would increase our understanding of the consequences of the deregulation of miRNAs during hepatocarcinogenesis. From this point of view, systematic and comprehensive target gene analyses for in silico systems biology models may be one option to resolve these issues.

miRNAs linked to inflammation-mediated hepatocarcinogenesis

Inflammation is considered to be a major cause of cancer [38, 39]. In the liver, hepatocarcinogenesis frequently occurs in persistently inflamed liver tissues caused by chronic hepatitis viral infection or non-alcoholic steatohepatitis. However, the molecular linkage between chronic inflammation and carcinogenesis is not well characterized.

Table 1 Upregulated miRNAs in hepatocarcinogenesis

miRNA	Expression levels	Targets	Main tested samples	References
miR-17-5p	Upregulated	p38 pathway	Cultured cells, human tissues	[52]
miR-18a	Upregulated	ER1a	Human tissues, cultured cells	[53]
miR-21	Upregulated	C/EBPb	Mouse CDAA model	[54]
	Upregulated	PTEN	Human tissues, cultured cells	[35]
miR-22	Upregulated	ERa, IL-1a	Human tissues, cultured cells, DEN model	[55]
miR-23a	Upregulated	PGC-1a,G6PC	Human tissues, cultured cells	[56]
miR-26a	Upregulated	Lin28B, Zcchc11	Human tissues, xenograft model	[57]
	Upregulated	NF-κB, IL-6 pathways	Human tissues	[58]
miR-30d	Upregulated	GNAI2	Human tissues, cultured cells	[59]
miR-100	Upregulated		Human tissues	[60]
miR-106b	Upregulated	APC	Human tissues, cultured cells	[61]
miR-122	Upregulated		Human tissues	[60]
miR-130b	Upregulated	TP53INP1	Human tissues, xenograft model	[62]
miR-135a	Upregulated	FOXM1, MTSS1	Human tissues, cultured cells, xenograft	[63]
miR-143	Upregulated	FNDC3B	Human tissues, HBX transgenic mouse	[64]
miR-146a	Upregulated in endothelial cells	BRCA, PDGFRA	Cultured cells	[65]
miR-151	Upregulated	FAK	Human tissues, cultured cells	[66]
	Upregulated	FAK, RhoGDIA	Human tissues, cultured cells	[67]
miR-155	Upregulated	SOCS1	Orthotropic transplant model	[68]
	Upregulated	DKK1, APC	Human tissues, cultured cells	[69]
	Upregulated	PTEN	Mouse CDAA model	[54]
miR-181	Upregulated	TIMP3	Mouse CDAA model	[70]
	Upregulated	CDX2, GATA6, NLK	Cultured cells	[71]
miR-183	Upregulated	AKAP12	Human tissues	[72]
miR-186	Upregulated	AKAP12	Human tissues	[72]
miR-200	Upregulated	NRF2 pathway	Rat HCC model,	[73]
miR-210	Upregulated	VMP1	Human tissues, cultured cells	[74]
miR-216a	Upregulated	TSLC1	Human tissues, cultured cells	[75]
miR-216a/217	Upregulated	PTEN, SMAD7	Cultured cells, Human tissues	[76]
miR-221	Upregulated	CDK inhibitors	Transgenic mouse	[77]
	Upregulated	p27, p57, Arnt	Primary hepatocytes	[78]
	Upregulated	Bmf	Cultured cells, human tissues	[79]
	Upregulated	p27, p57	Cultured cells, human tissues	[80]
miR-221/222	Upregulated	p27, DDIT4	Human tissues, mouse model	[81]
miR-224	Upregulated		Human tissues	[82]
	Upregulated	Atg5, Smad4, autophagy	Human tissues, HBV X transgenic mice	[83]
	Upregulated	API-5	Cultured cells, human tissues	[84]
	Upregulated		Human tissues	[85]
	Upregulated	API-5	Human tissues	[86]
miR-423	Upregulated	p21/waf1	Human tissues, cultured cells	[87]
miR-485-3p	Upregulated	MAT1, LIN28B	Human tissues, xenograft model	[88]
miR-490-3p	Upregulated	ERCIC3	Human tissues, cultured cells	[89]
miR-494	Upregulated	MCC	Human tissue, mouse liver cancer model	[90]
miR-495	Upregulated	MAT1, LIN28B	Human tissues, xenograft model	[88]
miR-517a	Upregulated		Human tissues, cultured cells	[91]
miR-657	Upregulated	TLE1, NF-κB	Human tissues, cultured cells	[92]
miR-664	Upregulated	MAT1, LIN28B	Human tissues, xenograft model	[88]
miR-1323	Upregulated		Human tissues	[93]

Table 2 Downregulated miRNAs in hepatocarcinogenesis

miRNA	Expression levels	Targets	Main tested samples	References
let-7a	Downregulated	STAT3	Cultured cells	[94]
let-7c	Downregulated		Human tissues, cultured cells	[95]
let-7g	Downregulated	COL12A	Cultured cells, human tissues	[96]
miR-7	Downregulated	PIK3CD	Cultured cells, human tissues	[97]
miR-10a	Downregulated	EphA4	Cultured cells	[98]
miR-10b	Downregulated		Human tissues	[99]
miR-15a/16	Downregulated		Cultured cells	[100]
miR-21	Downregulated		Human tissues	[82]
miR-26a	Downregulated	IL-6	Human tissues, xenograft model	[101]
	Downregulated	CyclinD2, E2	Cultured cells, mouse model	[102]
miR-29	Downregulated	Bcl2, Mcl1	Human tissues, cultured cells	[103]
miR-29b	Downregulated	MMP-2	Human tissues, cultured cell	[104]
miR-29c	Downregulated	SIRT1	Cultured cells	[105]
miR-34a	Downregulated	CCL22	Human tissues, cultured cells	[106]
miR-99a	Downregulated	PLK1	Human tissues, cultured cells	[107]
	Downregulated	IGF-1R	Human tissues, cultured cells	[108]
miR-100	Downregulated	PLK1	Human tissues, cultured cells	[107]
miR-101	Downregulated	EZH2, EED	Human tissues, cultured cells	[109]
	Downregulated		Human tissues, cultured cells	[95]
	Downregulated	Mcl1	Cultured cells, human tissues	[110]
	Downregulated	Fos	Human tissues, cultured cells	[111]
miR-122	Downregulated	c-Myc	Human tissues, cultured cells	[112]
	Downregulated		Cultured cells	[113]
	Downregulated	MTTP	Knockout mice	[32]
	Downregulated	IL6, TNF	Knockout mice	[31]
	Downregulated	IGF-1R	Human tissues	[114]
	Downregulated	Cyclin G1	Human tissues, cultured cells	[115]
miR-124	Downregulated	ROCK2, EZH2	Human tissues, cultured cells	[116]
	Downregulated	CDK6, VIM, SMYD3, IQGAP1	Human tissues, cultured cells	[117]
miR-125a/125b	Downregulated		Human tissues, cultured cells	[118]
miR-125b	Downregulated	SUV39H	Human tissues, cultured cells	[119]
	Downregulated	Mcl1, Bclw, IL6R	Human tissues, cultured cells	[120]
	Downregulated		Human tissues, cultured cells	[95]
	Downregulated	PIGF, MMP-2, MMP-9	Human tissues, cultured cells	[121]
	Downregulated	Lin28B	Human tissues, cultured cells	[122]
miR-139	Downregulated	ROCK2	Human tissues, cultured cells	[123]
miR-139-5p	Downregulated		Human tissues, cultured cells	[95]
miR-140-5p	Downregulated	TGFBR1, FGF9	Human tissues, cultured cells	[124]
		DNMT1	Knockout mice	[125]
miR-141	Downregulated	DLC-1	Human tissues	[126]
miR-145	Downregulated		Human tissues	[60]
	Downregulated	IRS1, IRS2, IGF-1R, b-catenin	Human tissues, cultured cells	[127]
	Downregulated		Human tissues	[85]
miR-148a	Downregulated	c-Met	Human tissues, cultured cells	[128]
	Downregulated	HRIP	Mouse xenograft model, cultured cells	[129]
	Downregulated	e-cadherin	Human tissues, cultured cells	[130]
	Downregulated	c-Myc	Cultured cells	[131]
miR-152	Downregulated	DNMT1, GSTP1, CDH1	Human tissues	[132]

Springer

Table 2 continued

| miRNA	Expression levels	Targets	Main tested samples	References
miR-195	Downregulated	NF-κB pathway	Cultured cells	[133]
	Downregulated	VEGF, VAV2, CDC42	Cultured cells, human tissues	[134]
	Downregulated	Cyclin D1, CDK6, E2F3	Cultured cells, human tissues	[135]
miR-198	Downregulated		Human tissues	[60]
miR-199a/b-3p	Downregulated	PAK4	Human tissues, cultured cells	[30]
miR-199b	Downregulated		Human tissues	[85]
miR-200a	Downregulated	H3 acetylation	Human tissues, cultured cells	[136]
miR-200b	Downregulated		Human tissues, cultured cells	[95]
miR-200c	Downregulated		Human tissues	[82]
miR-200	Downregulated		Human tissues	[82]
miR-203	Downregulated	ABCE1	Human tissues, cultured cells	[117]
miR-214	Downregulated	HDGF	Human tissues, cultured cells	[137]
miR-222	Downregulated		Human tissues	[82]
miR-223	Downregulated	STMN1	Human tissues	[138]
miR-224	Downregulated		Human tissues	[139]
miR-363-3p	Downregulated	c-Myc	Cultured cells	[131]
miR-375	Downregulated	ATG7	Human tissues, cultured cells	[140]
	Downregulated	AEG-1	Human tissues, cultured cells	[141]
miR-429	Downregulated	Rab18	Cultured cells	[142]
miR-449	Downregulated	c-MET	Xenograft, cultured cells	[143]
miR-520e	Downregulated	NIK	Human tissues, cultured cells	[69]
miR-612	Downregulated	AKT2	Cultured cells, human tissues	[144]
miR-637	Downregulated	STAT3 activation	Human tissues, cultured cells	[145]
miR-1271	Downregulated	GLP3	Human tissues, cultured cells	[99]

Fig. 2 A model bridging chronic inflammation and transformation by miRNA. Inflammation triggers activation of NF-κB, which leads to transcription of LIN28B. LIN28B inhibits the production of Let-7. Let-7 normally inhibits IL-6 expression, resulting in higher levels of IL-6 than are achieved by NF-κB activation. IL-6 mediated STAT3 activation is necessary for transformation and IL-6 activates NF-κB, completing a positive feedback loop

miRNAs, as a new class of gene expression regulators, may be involved in chronic inflammation-induced carcinogenesis and, in fact, several studies have clarified one such linkage, in which miRNAs may serve as a bridge between continuous inflammation and carcinogenesis.

A flagship report addresses a positive feedback loop of an inflammatory response mediated by NF-κB that activates Lin28B transcription (Fig. 2) [40]. LIN28B, which is an inhibitor of miRNA processing, reduces let-7 levels. Let-7 inhibits IL-6 expression, resulting in higher levels of IL-6 than achieved by NF-κB activation. IL-6-mediated STAT3 activation is necessary for transformation and IL-6 activates NF-κB, completing a positive feedback loop. Although the experiments mainly used MCF10A cells (breast cancer cells), a similar feedback loop was observed in HCC tissues. The authors termed these mechanisms an

Fig. 3 A model describing a positive feedback loop mediated by miRNAs from transient HNF4α inhibition to transformation. Transient silencing of HNF4α is mediated by miR-24 and miR-629, both of which are induced by STAT3 activation following IL-6 stimulation. miR-124, whose promoter region contains HNF4α-binding sites, targets IL-6R and, thus, HNF4α silencing results in reduced expression of miR-124 and enhanced expression of IL-6R and activation of STAT3, which induces miR-24 and miR-629. This microRNA feedback-inflammatory loop is thought to be crucial in IL-6-mediated liver cancer

"epigenetic switch" because the loop maintains the epigenetic transformed state even in the absence of induction by inflammation (Fig. 2).

Another report addressed hepatocarcinogenesis induced by transient inhibition of HNF4α (Fig. 3) [41]. HNF4α was reported to be involved in liver oncogenesis, although discrepant reports have also been published [42–44]. In that report, transient HNF4α silencing was sufficient to maintain cell transformation. Through a miRNA library screen, miR-24 and miR-629 were identified to target

HNF4α. Interestingly, both miRNAs were induced following HNF4α silencing, supporting their involvement in the HNF4α-dependent feedback loop. miR-24 and miR-629 contain the STAT3-binding motif in their promoter region. The authors showed that in response to IL-6, STAT3 binding to their promoters increased, resulting in miRNA expression. They also identified miR-124, whose promoter region contains HNF4α binding sites. miR-124 targets IL-6R and, thus, HNF4α silencing results in reduced expression of miR-124 and enhanced expression of IL-6R and activation of STAT3. The importance of these feedback loops was confirmed in vivo using a mouse HCC model induced by diethylnitrosamine. miR-124 delivery by cationic liposomes prevented tumor development. Thus, these microRNA feedback-inflammatory loops are important and can be a therapeutic target for liver cancer (Fig. 3) [41].

A recent paper reported a similar but distinct observation (Fig. 4). The authors found that when using DEN-induced foci of altered hepatocytes (FAH), LIN28-expressing cells are present in FAH, in which let-7 is down-regulated, resulting in the enhanced expression of IL-6, mediating the progression of malignancies from progenitors. An important difference between the cells in FAH and those in early hepatocarcinogenesis is that IL-6 signaling is autocrine, being mediated by reduced let-7 due to upregulation of LIN28B in FAH cells. This mechanism may contribute to malignant progression from HCC progenitor cells (Fig. 4) [45].

These three reports are from related research groups, and rely on the hypothesis that the IL-6-STAT3 pathway is crucial for hepatocarcinogenesis. Although IL-6 has been implicated as a growth factor in various epithelial cancers [46, 47], its relevance in hepatocarcinogenesis needs to be confirmed to determine the applicability and reproducibility of these findings to the clinical setting.

Fig. 4 A model bridging the malignant transformation of precursor cells and autocrine-mediated inflammation by microRNA. LIN28-expressing cells exist in the foci of altered hepatocytes, in which let-7 is downregulated, resulting in enhanced IL-6 expression, which mediates the progression of malignancies from progenitor cells